P53, p63 and Ki-67 assessment in HPV-induced cervical neoplasia

Romanian Journal of Morphology and Embryology

Volumn 50, Issue 3, 2008, Pages 357-361

  Vasilescu, Florina ^a   Ceausu M ^a,b   Tǎnase, Cristina ^b   Stǎnculescu, Ruxandra ^a,c   Vlǎdescu, Teodora ^c   Ceauşu, Zenaida ^c  

^a CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^b NATIONAL INSTITUTE FOR RESEARCH AND DEVELOPMENT IN MICROTECHNOLOGIES   (Romania)

^c Nephrology Clinic   (Romania)

Author keywords

Cervical cancer; Prognostic factors; Tumor suppressor genes

Indexed keywords

KI 67 ANTIGEN; PROTEIN P53; TP63 PROTEIN, HUMAN; TRANSACTIVATOR PROTEIN; TUMOR SUPPRESSOR PROTEIN;

ADULT; ARTICLE; CELL NUCLEUS; FEMALE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; METABOLISM; PATHOLOGY; PHYSIOLOGY; SQUAMOUS CELL CARCINOMA; UTERINE CERVIX TUMOR; VIROLOGY;

ADULT; CARCINOMA, SQUAMOUS CELL; CELL NUCLEUS; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMANS; KI-67 ANTIGEN; TRANS-ACTIVATORS; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS; UTERINE CERVICAL NEOPLASMS;

HUMAN PAPILLOMAVIRUS;

EID: 70349164552     PISSN: 12200522     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. CRUM C. P., The female genital tract. In: KUMAR V., FAUSTO N., ABBAS A. (eds), Robbins & Cotran Pathologic Basis of Disease, 7th edition, Elsevier-W. B. Saunders Press, 2005, 1098-1099.
2. PHELPS W. C., YEE C. L., MÜNGER K., HOWLEY P. M., The human papillomavirus type 16 E7 gene encodes transactivation and transformation functions similar to those of adenovirus E1A, Cell, 1988, 53(4):539-547.
3. SPITKOVSKY D., AENGENEYNDT F., BRASPENNING J., VON KNEBEL DOEBERITZ M., p-53-independent growth regulation of cervical cancer cells by the papillomavirus E6 oncogene, Oncogene, 1996, 13(5):1027-1035.
4. HSU S. M, RAINE L., FANGER H., Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures, J Histochem Cytochem, 1981, 29(4):577-580.
5. BUSSOLATI G., GUGLIOTTA P., Nonspecific staining of mast cells by avidin-biotin-peroxidase complexes (ABC), J Histochem Cytochem, 1983, 31(12):1419-1421.
6. YI W., WANG J. L., LI X. H., WEI L. H., Correlations of high-risk human papilloma viral load to cervical intraepithelial neoplasia grades, expression of Ki-67 and P6ink4a and follow-up, Ai Zheng, 2008, 27(5):520-524.
7. VAN HAMONT D., BULTEN J., SHIRANGO H., MELCHERS W. J., MASSUGER L. F., DE WILDE P. C., Biological behavior of CIN lesions is predictable by multiple parameter logistic regression models, Carcinogenesis, 2008, 29(4):840-845.
8. MULLER S., FLORES-STAINO C., SKYLDBERG B., HELLSTRÖM A. C., JOHANSSON B, HAGMAR B., WALLIN K. L., ANDERSSON S., Expression of p16INK4a and MIB-1 in relation to histopathology and HPV types in cervical adenocarcinoma, Int J Oncol, 2008, 32(2):333-340.
9. ARAFA M., BONIVER J., DELVENNE P., Detection of HPV-induced cervical (pre) neoplastic lesions: a tissue microarray (TMA) study, Appl Immunohistochem Mol Morphol, 2008, 16(5):422-432.
10. LEE J. J., KIM S., YEOM Y. I., HEO D. S., Enhanced specificity of the p53 family proteins-based adenoviral gene therapy in uterine cervical cancer cells with E2F1-responsive promoters, Cancer Biol Ther, 2006, 5(11):1502-1510.
11. ZHANG G., SUN L., LI Z., SI L., SONG T., HUANG C., ZHANG W., HPV-16E6 can induce multiple site phosphorylation of p53, Oncol Rep, 2009, 21(2):371-377.
12. KHUNAMORNPONG S., SIRIAUNKGUL S., MANUSIRIVITHAYA S., SETTAKORN J., SRISOMBOON J., PONJAROEN J., THORNER P. S., Prognostic value of p53 expression in early stage cervical carcinoma treated by surgery, Asian Pac J Cancer Prev, 2008, 9(1):48-52.
13. MALISIC E., JANKOVIC R., MAJKIC M., DOBRICIC J., RADULOVIC S., p53 gene alterations and human papillomavirus type 16 infection in early stages of cervical carcinoma in Serbia, J BUON, 2008, 13(4):525-532.
14. YIM E. K., TONG S. Y., HO E. M., BAE J. H., UM S. J., PARK J. S., Anticancer effects on TACC3 by treatment of paclitaxel in HPV-18 positive cervical carcinoma cells, Oncol Rep, 2009, 21(2):549-557.
15. LIN Z., NAN Y., ZHANG X., ZHAO Y., KIM C., KIM I., Reverse transcription-polymerase chain reaction and western blotting analysis for detection of p63 isoforms in uterine cervical cancers, Int J Gynecol Cancer, 2006, 16(4):1643-1647.
16. WISE-DRAPER T. M., MORREALE R. J., MORRIS T. A., MINTZ- COLE R. A., HOSKINS E. E., BALSITIS S. J., HUSSEINZADEH N., WITTE D. P., WIKENHEISER-BROKAMP K. A., LAMBERT P. F., WELLS S. I., DEK proto-oncogene expression interferes with the normal epithelial differentiation program, Am J Pathol, 2009, 174(1):71-81.
17. MCCLUGGAGE W. G., Immunohistochemistry as a diagnostic aid in cervical pathology, Pathology, 2007, 39(1):97-111.
18. GARCIA M. T., ACAR B. C., JORDA M., GOMEZ-FERNANDEZ C., GANJEI-AZAR P., Use of p63 for distinction of glandular versus squamous lesions in cervicovaginal specimens, Cancer, 2007, 111(1):54-57.
19. MARTENS J. E., ARENDS J., VAN DER LINDEN P. J., DE BOER B. A., HELMERHORST T. J., Cytokeratin 17 and p63 are markers of the HPV target cell, the cervical stem cell, Anticancer Res, 2004, 24(2B):771-775.
20. TEISSIER S., BEN KHALIFA Y., MORI M., PAUTIER P., DESAINTES C., THIERRY F., A new E6/P63 pathway, together with a strong E7/E2F mitotic pathway, modulates the transcriptome in cervical cancer cells, J Virol, 2007, 81(17):9368-9376.